Despite the escalating Russia-Ukraine conflict and ongoing Covid-19 pandemic, SET-listed Mega Lifesciences, a producer of pharmaceuticals and food supplements, vows to continue to expand its business both domestically and overseas this year.
Chief executive Vivek Dhawan said the company planned to allocate 625 million baht to expand its business between 2022 and 2023. Of the total, 414 million baht will be used for the consolidation of its manufacturing operations and capacity expansion in Thailand, with 46 million baht to be used in the field of environmental, social, and governance (ESG). The remaining 165 million baht is to be spent on an existing pharmaceutical plant in Indonesia.
"Consumer healthcare is an emerging trend. The way forward is disease prevention rather than struggling for a cure. So our business is a sunrise industry,'' Mr Dhawan said.
